Deans' stroke musings: GlobeNewswire NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, October 15, 2024

GlobeNewswire NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)

What does your competent? doctor think of the research behind this? Or is your doctor so sure they can get you 100% recovered just from their training in medical school? If so, YOU DON'T HAVE A FUNCTIONING STROKE DOCTOR, DO YOU?

I find no articles on troculeucel in Google Scholar so I have no clue where they have published research on this.

NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)

SANTA ANA, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today announced acceptance of an oral presentation on the potential of troculeucel in patients with neurodegenerative disease and stroke, at the 16^th World Stroke Congress (“WSC 2024”) to be held in Abu Dhabi, UAE from October 23–26, 2024. Although accepted as an oral presentation, NKGen has opted to showcase troculeucel results in poster format.

E-Poster Details:

Title:	Therapeutic potential of expanded SNK01 (activated autologous natural killer cells) post-stroke to reduce neuroinflammation, inflammation-mediated cell death, and damage
Authors:	Paul Y. Song, Lucia Hui, Blanca Isaura Acosta Gallo, César Alejandro Amescua, Katia Betito, Sean Hong, Clemente Humberto Zúñiga Gil
Poster Number:	1389
Session 1:	Free Communications 09: Health Services & Implementation of Stroke Care
Date/Time/Location:	Friday, October 25, 2024, 8:00 am – 9:30 am GST; Hall F
Session 2:	Onsite and Live Streamed Session – Plenary 03: Plenary, Awards & Late Breaking
Date/Time/Location:	Friday, October 25, 2024, 10:00 am – 11:30 am GST; Hall A/Plenary

A copy of the poster will be added to the Scientific Publications page of the Company’s website at https://nkgenbiotech.com/ once the presentation has concluded.